## (1) UPL

## Consolidated Unaudited Results

$$
\text { Q3 FY } 2019
$$

Investor Presentation: January 31, 2019


## Financial Results: Q3 FY 2019

| Particulars | Q3 FY 2019 |  |  | Q3 FY 2018 |  |  | Change |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | INR Crore | INR Crore | \% | INR Crore | INR Crore | \% | \% |
| Gross Revenues <br> Domestic Revenues International Revenues <br> Cost of Goods Sold | 486 4,435 | $4,921$ $2,834$ | $\begin{array}{r} 100 \% \\ 10 \% \\ 90 \% \\ \\ 58 \% \end{array}$ | 614 3,580 | $4,194$ $2,391$ | $\begin{array}{r} 100 \% \\ 15 \% \\ 85 \% \\ \\ 57 \% \end{array}$ | $\begin{array}{r} 17 \% \\ -21 \% \\ 24 \% \\ \\ 19 \% \end{array}$ |
| Gross Margin |  | 2,087 | 42.4\% |  | 1,803 | 43.0\% | 16\% |
| Overheads |  | 1,071 | 22\% |  | 974 | 23\% | 10\% |
| EBIDTA |  | 1,016 | 20.6\% |  | 829 | 19.8\% | 23\% |
| Other Income / (Loss) <br> Depreciation \& Amortisation Interest \& Finance Charges |  | -41 182 202 | $\begin{array}{r} -1 \% \\ 4 \% \\ 4 \% \end{array}$ |  | 6 169 111 | $0 \%$ $4 \%$ $3 \%$ | $\begin{array}{r} -783 \% \\ 8 \% \\ 82 \% \end{array}$ |
| Profit Before Tax |  | 591 | 12.0\% |  | 555 | 13.2\% | 6\% |
| Tax provision * |  | 28 | 1\% |  | -14 | 0\% | - 300\% |
| Profit After Tax * |  | 563 | 11.4\% |  | 569 | 13.6\% | -1\% |
| Income/(Loss) from Associates Minority Interest |  | -4 7 | 0\% |  | 17 | $\begin{aligned} & 0 \% \\ & 0 \% \end{aligned}$ | $\begin{array}{r} -124 \% \\ 40 \% \end{array}$ |
| Profit before exceptional item |  | 552 | 11.2\% |  | 581 | 13.9\% | -5\% |
| Exceptional items |  | 91 | 2\% |  | 7 | 0\% | 1200\% |
| Net Profit for the period |  | 461 | 9.4\% |  | 574 | 13.7\% | -20\% |

- Q3 FY 2018 Tax provision included excess provision of tax written back and minimum alternate tax credit entitlement relating to earlier periods of Rs. 98 crore and Rs. 55 crore of reduction in Deferred Tax Asset due to US Tax Reforms. After adjusting these figures the Tax provision would be Rs. 29 crore.
- Resultantly, the growth in Profit After Tax will be 7\%


## Sales Analysis: Q3 FY 2019

## Total Growth <br> 18\%

Constant Currency Growth 13\%


Exchange
Price
Volume

## Revenue by Region: Q3 FY 2019 vs. Q3 FY 2018

| Region | Q3 FY 2019 |  | Q3 FY 2018 |  | Change |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | INR Crore | $\%$ | INR Crore | $\%$ | INR Crore | $\%$ |
| India | 486 | $10 \%$ | 614 | $15 \%$ | $(128)$ | $-21 \%$ |
| Latin America | 2,284 | $46 \%$ | 1,806 | $43 \%$ | 478 | $26 \%$ |
| Europe | 511 | $10 \%$ | 374 | $9 \%$ | 137 | $37 \%$ |
| Rest of World | 774 | $16 \%$ | 687 | $16 \%$ | 87 | $13 \%$ |
| North America | 866 | $18 \%$ | 713 | $17 \%$ | 153 | $21 \%$ |
| Total | 4,921 | $\mathbf{1 0 0} \%$ | 4,194 | $\mathbf{1 0 0} \%$ | $\mathbf{7 2 7}$ | $\mathbf{1 7} \%$ |

## Financial Results: 9 Months FY 2019

| Particulars | 9 Months FY 2019 |  |  | 9 Months FY 2018 |  |  | Change |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | INR Crore | INR Crore | \% | INR Crore | INR Crore | \% | \% |
| Gross Revenues <br> Domestic Revenues International Revenues Cost of Goods Sold | $\begin{array}{r} 2,811 \\ 10,501 \end{array}$ | $13,312$ $7,586$ | $\begin{array}{r} 100 \% \\ 21 \% \\ 79 \% \\ \\ 57 \% \end{array}$ | $\begin{aligned} & 2,729 \\ & 8,958 \end{aligned}$ | $\begin{array}{r} 11,687 \\ 6,685 \end{array}$ | $\begin{array}{r} 100 \% \\ 23 \% \\ 77 \% \\ 57 \% \end{array}$ | $\begin{array}{r} 14 \% \\ 3 \% \\ 17 \% \\ 13 \% \end{array}$ |
| Gross Margin |  | 5,726 | 43.0\% |  | 5,002 | 42.8\% | 14\% |
| Overheads |  | 3,024 | 23\% |  | 2,704 | 23\% | 12\% |
| EBIDTA |  | 2,702 | 20.3\% |  | 2,298 | 19.7\% | 18\% |
| Other Income/(Loss) <br> Depreciation \& Amortisation <br> Interest \& Finance Charges |  | 12 538 558 | $0 \%$ $4 \%$ $4 \%$ |  | 82 491 373 | $1 \%$ $4 \%$ $3 \%$ | $\begin{array}{r} -85 \% \\ 10 \% \\ 50 \% \end{array}$ |
| Profit Before Tax |  | 1,618 | 12.2\% |  | 1,516 | 13.0\% | 7\% |
| Tax provision * |  | 196 | 1\% |  | 109 | 1\% | 80\% |
| Profit After Tax* |  | 1,422 | 28.9\% |  | 1,407 | 12.0\% | 1\% |
| Income/(Loss) from Associates Minority Interest |  | -14 15 | $\begin{aligned} & 0 \% \\ & 0 \% \end{aligned}$ |  | -57 7 | $\begin{aligned} & 0 \% \\ & 0 \% \end{aligned}$ | $\begin{aligned} & -75 \% \\ & 114 \% \end{aligned}$ |
| Profit before exceptional item |  | 1,393 | 10.5\% |  | 1,343 | 11.5\% | 4\% |
| Exceptional items |  | 152 | 1\% |  | 57 | 0\% | 167\% |
| Net Profit for the period |  | 1,241 | 9.3\% |  | 1,286 | 1.1.0\% | -3\% |

## Note : Revenue in PY is net of Excise to have correct comparison post GST.

- 9 months FY 2018 Tax provision included excess provision of tax written back and minimum alternate tax credit entitlement relating to earlier periods of Rs. 98 crore and Rs. 55 crore of reduction in Deferred Tax Asset due to US Tax Reforms. After adjusting these figures the Tax provision would be Rs. 152 crore.
- Resultantly, the growth in Profit After Tax will be 4\%


## Sales Analysis: 9 Months FY 2019



## Revenue by Region: 9 Months FY 2019 vs. 9 Months FY 2018

| Region | 9 Months FY 19 |  | 9 Months FY 18 |  | Change |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | INR Crore | $\%$ | INR Crore | $\%$ | INR Crore | $\%$ |
| India | 2,811 | $21 \%$ | 2,729 | $23 \%$ | 82 | $3 \%$ |
| Latin America | 4,890 | $37 \%$ | 3,927 | $34 \%$ | 963 | $25 \%$ |
| Europe | 1,526 | $11 \%$ | 1,322 | $11 \%$ | 204 | $15 \%$ |
| Rest of World | 2,078 | $16 \%$ | 1,922 | $16 \%$ | 156 | $8 \%$ |
| North America | 2,007 | $15 \%$ | 1,787 | $15 \%$ | 220 | $12 \%$ |
| Total | $\mathbf{1 3 , 3 1 2}$ | $\mathbf{1 0 0} \%$ | $\mathbf{1 1 , 6 8 7}$ | $\mathbf{1 0 0} \%$ | $\mathbf{1 , 6 2 5}$ | $\mathbf{1 4 \%}$ |

## India

INR in crore


- Sweep Power (non-selective Herbicide) crossed liquidation of $1,000 \mathrm{KL}$ in year of launch
- Shagun (wheat herbicide) grew $50 \%$ YoY
- Launched Ranman (Fungicide) for control of downey mildew in the lucrative grape segment
- Biostimulants continue to grow (Ganexia, Macarena, Copio)
- Inconsistency in rainfall has resulted in a decline in India market
- Government decision to restrict / ban use of organophosphorus compounds in several states impacted sales


## Latin America (Incl. Brazil)

INR in crore

| Change | 26\% |
| :---: | :---: |
|  |  |
| 1,806 |  |
|  |  |
| Q3 FY 2018 | Q3 FY 2019 |



- AMUSE - A resistance management spray program - have pushed sales of UNIZEB (Fungicide) family in South Cone region.
- New Government has led to stability of BRL thereby improving market sentiment.
- Successful launch and acceptance of STRIM (Herbicide) in Argentina and South Cone.
- Overall the market in Brazil grew by $18 \%$ with Insecticide segment leading the way. Sperto (Insecticide) gaining leadership position.


## Europe

INR in crore


- UPL continued to grow in spite of the overall European market down by $10 \%$
- Q3 sales have been strong, particularly for Mancozeb WG in France, for Metamitron technical in Russia
- Better planning of Metamitron led to improved volumes in spite of drop in sugar beat acreages
- Good growth in Sulphur and Copper products on back of improved weather conditions in Italy and Spain
- Across Europe, we were able to pass on the cost increase to the market which has helped in maintaining margins
- Propanil Sales were impacted as annual permit was not granted


## Rest of World

INR in crore


- Tarang - a non-selective Herbicide - well accepted in Indonesia, Philippines and Vietnam led to strong volume growth
- Significant growth of Ulala (Insecticide) in Pakistan
- STRIM \& Fist (Herbicides) Super launched in China
- Growth in Africa continues


## North America

INR in crore


- Registration of Lifeline (Herbicide) in Canada (soft launch in Q3)
- Good advance collection from distribution - assured sales
- Business alliance with Americot - a cotton seed company - will drive sales of UPL Branded products in cotton
- Lifeline continues to grow despite increase in acreage of Dicamba-tolerant seeds


## Working Capital Analysis



## Financial Results for April - December 2018

|  | Particulars | Quarter ended 31.12.2018 (Unaudited) | Quarter ended $30.09 .2018$ <br> (Unaudited) | Quarter ended 31.12.2017 <br> (Unaudited) | Nine Months ended 31.12.2018 <br> (Unaudited) | Nine Months ended 31.12.2017 <br> (Unaudited) | Year ended <br> 31.03.2018 <br> (Audited) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Revenue from Operations | 4,921 | 4,257 | 4,194 | 13,312 | 11,815 | 17,506 |
| II | Other Income | 37 | 32 | 119 | 192 | 296 | 414 |
| III | Total Income ( $1+$ II) | 4,958 | 4,289 | 4,313 | 13,504 | 12,111 | 17,920 |
| IV | Expenses |  |  |  |  |  |  |
|  | a) Consumption of Raw Materials, Packing Material, Traded goods \& Changes in inventories of Finished goods, stock in trade \& Work in progress | 2,223 | 1,876 | 1,907 | 5,938 | 5,210 | 8,112 |
|  | b) Excise duty | - | - | - | - | 128 | 128 |
|  | c) Employee benefits expense | 504 | 467 | 425 | 1,425 | 1,283 | 1,713 |
|  | d) Finance Costs | 202 | 181 | 111 | 558 | 373 | 783 |
|  | e) Depreciation and Amortisation expense | 182 | 181 | 169 | 538 | 491 | 675 |
|  | f) Exchange Difference (net) on trade recievables \& trade payables | 78 | 52 | 113 | 180 | 214 | 11 |
|  | g) Other Expenses | 1,178 | 1,075 | 1,033 | 3,247 | 2,896 | 4,037 |
|  | Total Expenses | 4,367 | 3,832 | 3,758 | 11,886 | 10,595 | 15,459 |
| V | Profit/Loss before Exceptional items and tax (III - IV) | 591 | 457 | 555 | 1,618 | 1,516 | 2,461 |
| VI | Exceptional Items (Income)/Expense | 91 | 57 | 7 | 152 | 57 | 63 |
| VII | Profit from Ordinary Activities before Tax (V-VI) | 500 | 400 | 548 | 1,466 | 1,459 | 2,398 |
| VIII | Tax expenses | 28 | 116 | (14) | 196 | 109 | 275 |
| IX | Net Profit from Continuing Activities after Tax (VII-VIII) | 472 | 284 | 562 | 1,270 | 1,350 | 2,123 |
| X | Add : Share of Profit/(loss) from Associates/Joint Ventures | (4) | (8) | 17 | (14) | (57) | (93) |
| XI | Net Profit for the period | 468 | 276 | 579 | 1,256 | 1,293 | 2,030 |
|  | Attributable to: |  |  |  |  |  |  |
|  | Equity holders of the parent | 461 | 270 | 574 | 1,241 | 1,286 | 2,022 |
|  | Non controlling Interests | 7 | 6 | 5 | 15 | 7 | 8 |

## Thank You

(1) $\overline{U P L}$

